Publications

Our R&D team is hometo an impressive constellation of scientists drawn from a wide array of disciplines. As experts in their field, our people regularly publish their work in prestigious journals. We also engage with the wider scientific community to conduct research and co-author papers. See below the list of publications by our people:

  1. Nita Bhandari, Temsunaro Rongsen-Chandola, Ashish Bavdekar, Jacob John, Kalpana Antony, Sunita Taneja, Nidhi Goyal, Anand Kawade, Gagandeep Kang, Sudeep Singh Rathore, Sanjay Juvekar, Jayaprakash Muliyil, Alok Arya, Hanif Shaikh, Vinod Abraham, Sudhanshu Vrati, Michael Proschan, Robert Kohberger, Georges Thiry, Roger Glass, Harry B Greenberg, George Curlin, Krishna Mohan, G V J A Harshavardhan, Sai Prasad, T S Rao, John Boslego, Maharaj Kishan Bhan. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life. Vaccine. Vaccine 2014 Aug;32 Suppl 1:A110-6.
  2. V H Basavaraj, G Sampath, Nagendra R Hegde, V Krishna Mohan, Krishna M Ella. Evaluation of safety and immunogenicity of HNVAC, an MDCK-based H1N1 pandemic influenza vaccine, in Phase I single centre and Phase II/III multi-centre, double-blind, randomized, placebo-controlled, parallel assignment studies. Vaccine. Vaccine 2014 Jul 21;32(35):4592-7. Epub 2014 May 21.
  3. Nagendra R Hegde, Deepak Kumar, P Panduranga Rao, P Krishna Kumari, Yashpal Kaushik, R Ravikrishnan, Sai D Prasad, Krishna M Ella. Development and preclinical testing of HNVAC, a cell culture-based H1N1 pandemic influenza vaccine from India. Vaccine.Vaccine 2014 Jun 5;32(29):3636-43. Epub 2014 May 5.
  4. Maharaj K Bhan, Roger I Glass, Krishna M Ella, Nita Bhandari, John Boslego, Harry B Greenberg, Krishna Mohan, George Curlin, T S Rao. Team science and the creation of a novel rotavirus vaccine in India: a new framework for vaccine development. Lancet.Lancet 2014 Jun 12;383(9935):2180-3. Epub 2014 Mar 12.
  5. Ashwani Kumar,Inshad Ali Khan,Parduman Raj Sharma,Sumathy K, and Krishna M. Ella. Evaluation of activity of recombinant lysostaphin against isolates of meticillin-resistant Staphylococcus aureus from Indian hospitals. J Med Microbiol. May 2014 63:763-766; published ahead of print March 12, 2014.
  6. Sumathy K., Ella K.M. Genetic diversity of Chikungunya virus, India 2006-2010: evolutionary dynamics and serotype analyses. J Med Virol. 2012 Mar;84(3):462-70.
  7. Babu P.V. An Indian manufacturer’s perspective for harmonization of guidelines for similar biotherapeutic products. Biologicals.2011 Sep; 39 (5) 300-3.Epub 2011 Aug 4.
  8. Venkatesan R., A. Praveen Kumar and V.K. Srinivas. A challenge study to assess the protective efficacy of typhoid Vi-Polysaccharide-protein conjugate vaccine in laboratory animals. Int. J. Curr. Sci., 1(2011): 45-49.
  9. Ashok Raja Chairmandurai, Srinivas Vellimedu Kanappa, Krishna Mohan Vadrevu, Uday Kumar Putcha, Vijayalakshmi Venkatesan. Recombinant Human Epidermal Growth Factor Alleviates Gastric Antral Ulcer Induced by Naproxen: A Non-steroidal Anti-Inflammatory Drug. Gastroenterology Research.2010;3(3):125-133.
  10. Sampath G, Madhusudana SN, Sudarshan MK, Ashwathnarayana DH, Mahendra BJ, Ullas TP, Mohan K, Madhusudhan SK, Ravish HS. Immunogenicity and safety study of Indirab: a Vero cell based chromatographically purified human rabies vaccine. Vaccine. 2010 May 28;28 (24):4086-90.
  11. Venkatesan R. and V.K. Srinivas. Development of Typhoid Vi-Capsular Polysaccharide Tetanus Toxoid-Conjugate Vaccine: Immunogenicity Studies in Balb/c Mice. Advanced Biotech, 10 (2010): 09-11.
  12. Nita Bhandari, Pooja Sharma, Sunita Taneja, Tivendra Kumar, Temsunaro Rongsen-Chandola, Mohan Babu Appaiahgari, Arpita Mishra, Shakti Singh, Sudhanshu Vrati, and the Rotavirus Vaccine Development group. A Dose-Escalation safety and Immunogenicity Study of Live Attenuated Oral rotavirus Vaccine 116E in Infants: A Randomized, Double-Blind, Placebo- Controlled Trial. Journal of Infectious Diseases: 2009 (1) 421-429.
  13. Cherish Babu P.V., Srinivas V.K., Krishna Mohan V and Krishna Ella. Renaturation, Purification and Characterization of Streptokinase expressed as Inclusion body in Recombinant E. coli. J. Chromatogr. B 861(2008), 218-226.
  14. Khajuria A, Gupta A, Suden P, Singh S, Malik F, Singh J, Gupta BD, Suri KA, Srinivas VK, Ella K, Qazi GN. Immunomodulatory activity of biopolymeric fraction BOS 2000 from Boswellia serrata. Phytother Res. 22 (2008), 340-348.
  15. Sharma K, Cherish Babu P.V, Sasi P, Srinivas V.K, Krishna Ella., and Krishna Mohan V. Recombinant Human Epidermal Growth Factor Inclusion Body Solubilization and Refolding at Large Scale using Expanded-Bed Adsorption Chromatography from Escherichia coli. Prot. Exp. Purif. 60(2008) 7-14.
  16. G.Ravi, Krishna Ella, M.Lakshmi Narasu. Development of pilot scale production process and characterization of a recombinant multiepitope malarial vaccine candidate FALVAC-1A expressed in Escherichia coli. Prot. Exp. Purif. 61(2008) 57-64.
  17. Anamika Khajuria, Amit Gupta, Fayaz Malik, Surjeet Singh, Jaswant Singh, B.D. Gupta, K.A. Suri, Pankaj Suden, V.K. Srinivas, Krishna Ella and G.N. Qazi. A new vaccine adjuvant (BOS 2000) a potent enhancer mixed Th1/Th2 immune responses in mice immunized with HBsAg. Vaccine. 25 (2007) 4586–4594.
  18. V.K. Mohan. Recombinant human epidermal growth factor (REGEN-DTM 150): Effect on healing of diabetic foot ulcers. Diabetes Res. Clin. Pract. 78 (2007), 405-411.
  19. Dr.Rajesh Kesavan, Dr.Vijay Viswanathan, Ms.Sivagami, Ms.Kavitha, Dr.Mary Babu, Ms.Ramya. Dr. V. Krishna Mohan. Efficacy of Recombinant Human Epidermal Growth Factor (Regen D 150) in Healing Diabetic Foot Ulcers. Diabetes Res ClinPract. 2007 Dec;78(3):405-11. Epub 2007 Jul 25.
  20. Sabitha P., Prabha Adhikari M.R., Chowdary Abhijit, Prabhu Malathi, Soofi mohammad, Shetty Meenakshi, Kamath Asha, Lokaranjan S.S., Bangera S.S. Comparison of the immunogenicity and safety of two different brands of salmonella typhi VI capsular polysaccharide vaccine. Indian J Med Sci 2004;58:141-9.
  21. Lancet 2017. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Celina Jin, Malick M Gibani, Maria Moore, Helene B Juel, Elizabeth Jones, James Meiring, Victoria Harris, Jonathan Gardner, Anna Nebykova, Simon A Kerridge, Jennifer Hill, Helena Thomaides-Brears, Christoph J Blohmke, Ly-Mee Yu, Brian Angus, Andrew J Pollard.
  22. Scientific Reports 2017. Protective efficacy of Zika vaccine in AG129 mouse model. K. Sumathy, Bharathi Kulkarni, Ravi Kumar Gondu, Sampath Kumar Ponnuru, Nagaraju Bonguram, Rakesh Eligeti, SindhujaGadiyaram, Usha Praturi, Bhushan Chougule, LathaKarunakaran& Krishna M. Ella. 7:46375
  23. Nita Bhandari, TemsunaroRongsen-Chandola, Ashish Bavdekar, Jacob John, Kalpana Antony, SunitaTaneja, Nidhi Goyal, Anand Kawade, Gagandeep Kang, Sudeep Singh Rathore, Sanjay Juvekar, JayaprakashMuliyil, Alok Arya, Hanif Shaikh, Vinod Abraham, SudhanshuVrati, Michael Proschan, Robert Kohberger, Georges Thiry, Roger Glass, Harry B Greenberg, George Curlin, Krishna Mohan, G V J A Harshavardhan, Sai Prasad, T S Rao, John Boslego, Maharaj Kishan Bhan. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life. Vaccine 2014 Aug; 32 Suppl 1:A110-6.
  24. Nita Bhandari, TemsunaroRongsen-Chandola, Ashish Bavdekar, Jacob John, Kalpana Antony, SunitaTaneja, Nidhi Goyal, Anand Kawade, Gagandeep Kang, Sudeep Singh Rathore, Sanjay Juvekar, JayaprakashMuliyil, Alok Arya, Hanif Shaikh, Vinod Abraham, SudhanshuVrati, Michael Proschan, Robert Kohberger, Georges Thiry, Roger Glass, Harry B Greenberg, George Curlin, Krishna Mohan, G V J A Harshavardhan, Sai Prasad, T S Rao, John Boslego, Maharaj Kishan Bhan. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet 2014. (383),9935, p2136–2143
  25. Vadrevu Krishna Mohan Vineeth Varanasi Anit Singh Marcela F. Pasetti Myron M. Levine Ramasamy Venkatesan Krishna M. Ella. Safety and Immunogenicity of a Vi Polysaccharide–Tetanus Toxoid Conjugate Vaccine (Typbar-TCV) in Healthy Infants, Children, and Adults in Typhoid Endemic Areas: A Multicenter, 2-Cohort, Open-Label, Double-Blind, Randomized Controlled Phase 3 Study. Clinical Infectious Diseases 2015. 61(3), 393–402.
  26. Singh A, Mitra M, Sampath G, Venugopal P, Rao JV, Krishnamurthy B, Gupta MK, Sri Krishna S, Sudhakar B, Rao NB, Kaushik Y, Gopinathan K, Hegde NR, Gore MM, Krishna Mohan V, Ella KM. A Japanese Encephalitis Vaccine from India Induces Durable and Cross-protective Immunity against Temporally and Spatially Wide-ranging Global Field Strains.Journal of Infectious Diseases. 2015 Sep 1;212(5):715-25.

Remaining Publications:

  1. TemsunaroRongsen-Chandola, SunitaTaneja, Nidhi Goyal, Kalpana Antony, Kiran Bhatia, Deepal More, Nita Bhandari, Iksung Cho, Krishna Mohan, Sai Prasad, GVJA Harshavardhan, TatahiSurender Rao, SudhanshuVrati, Maharaj Kishan Bhan. ROTAVAC® does not interfere with the immune response to childhood vaccines in Indian infants: A randomized placebo controlled trial. Heliyon 2017.
  2. V H Basavaraj, G Sampath, Nagendra R Hegde, V Krishna Mohan, Krishna M Ella. Evaluation of safety and immunogenicity of HNVAC, an MDCK-based H1N1 pandemic influenza vaccine, in Phase I single centre and Phase II/III multi-centre, double-blind, randomized, placebo-controlled, parallel assignment studies. Vaccine. Vaccine 2014 Jul 21;32(35):4592-7. Epub 2014 May 21.
  3. Nagendra R Hegde, Deepak Kumar, P Panduranga Rao, P Krishna Kumari, Yashpal Kaushik, R Ravikrishnan, Sai D Prasad, Krishna M Ella. Development and preclinical testing of HNVAC, a cell culture-based H1N1 pandemic influenza vaccine from India. Vaccine. Vaccine 2014 Jun 5;32(29):3636-43. Epub 2014 May 5.
  4. Maharaj K Bhan, Roger I Glass, Krishna M Ella, Nita Bhandari, John Boslego, Harry B Greenberg, Krishna Mohan, George Curlin, T S Rao. Team science and the creation of a novel rotavirus vaccine in India: a new framework for vaccine development. Lancet. Lancet 2014 Jun 12;383(9935):2180-3. Epub 2014 Mar 12.
  5. Ashwani Kumar, Inshad Ali Khan,Parduman Raj Sharma,Sumathy K, and Krishna M. Ella. Evaluation of activity of recombinant lysostaphin against isolates of meticillin-resistant Staphylococcus aureus from Indian hospitals. J Med Microbiol. May 2014 63:763-766; published ahead of print March 12, 2014.
  6. Sumathy K., Ella K.M. Genetic diversity of Chikungunya virus, India 2006-2010: evolutionary dynamics and serotype analyses. J Med Virol. 2012 Mar;84(3):462-70.
  7. Babu P.V. An Indian manufacturer’s perspective for harmonization of guidelines for similar biotherapeutic products. Biologicals.2011 Sep; 39 (5) 300-3.Epub 2011 Aug 4.
  8. Venkatesan R., A. Praveen Kumar and V.K. Srinivas. A challenge study to assess the protective efficacy of typhoid Vi-Polysaccharide-protein conjugate vaccine in laboratory animals. Int. J. Curr. Sci., 1(2011): 45-49.
  9. Ashok Raja Chairmandurai, Srinivas VellimeduKanappa, Krishna Mohan Vadrevu, Uday Kumar Putcha, Vijayalakshmi Venkatesan. Recombinant Human Epidermal Growth Factor Alleviates Gastric Antral Ulcer Induced by Naproxen: A Non-steroidal Anti-Inflammatory Drug. Gastroenterology Research.2010;3(3):125-133.
  10. Sampath G, Madhusudana SN, Sudarshan MK, Ashwathnarayana DH, Mahendra BJ, Ullas TP, Mohan K, Madhusudhan SK, Ravish HS. Immunogenicity and safety study of Indirab: a Vero cell based chromatographically purified human rabies vaccine. Vaccine. 2010 May 28;28 (24):4086-90.
  11. Venkatesan R. and V.K. Srinivas. Development of Typhoid Vi-Capsular Polysaccharide Tetanus Toxoid-Conjugate Vaccine: Immunogenicity Studies in Balb/c Mice. Advanced Biotech, 10 (2010): 09-11.
  12. Nita Bhandari, Pooja Sharma, SunitaTaneja, Tivendra Kumar, TemsunaroRongsen-Chandola, Mohan Babu Appaiahgari, Arpita Mishra, Shakti Singh, SudhanshuVrati, and the Rotavirus Vaccine Development group. A Dose-Escalation safety and Immunogenicity Study of Live Attenuated Oral rotavirus Vaccine 116E in Infants: A Randomized, Double-Blind, Placebo- Controlled Trial. Journal of Infectious Diseases: 2009 (1) 421-429.
  13. Cherish Babu P.V., Srinivas V.K., Krishna Mohan V and Krishna Ella. Renaturation, Purification and Characterization of Streptokinase expressed as Inclusion body in Recombinant E. coli. J. Chromatogr. B 861(2008), 218-226.
  14. Cherish Babu P.V., Srinivas V.K., Krishna Mohan V and Krishna Ella. Renaturation, Purification and Characterization of Streptokinase expressed as Inclusion body in Recombinant E. coli. J. Chromatogr. B 861(2008), 218-226.
  15. Khajuria A, Gupta A, Suden P, Singh S, Malik F, Singh J, Gupta BD, Suri KA, Srinivas VK, Ella K, Qazi GN. Immunomodulatory activity of biopolymeric fraction BOS 2000 from Boswelliaserrata. Phytother Res. 22 (2008), 340-348.
  16. Sharma K, Cherish Babu P.V, Sasi P, Srinivas V.K, Krishna Ella., and Krishna Mohan V. Recombinant Human Epidermal Growth Factor Inclusion Body Solubilization and Refolding at Large Scale using Expanded-Bed Adsorption Chromatography from Escherichia coli. Prot. Exp. Purif. 60(2008) 7-14.
  17. G.Ravi, Krishna Ella, M.LakshmiNarasu. Development of pilot scale production process and characterization of a recombinant multiepitope malarial vaccine candidate FALVAC-1A expressed in Escherichia coli. Prot. Exp. Purif. 61(2008) 57-64.
  18. AnamikaKhajuria, Amit Gupta, Fayaz Malik, Surjeet Singh, Jaswant Singh, B.D. Gupta, K.A. Suri, Pankaj Suden, V.K. Srinivas, Krishna Ella and G.N. Qazi. A new vaccine adjuvant (BOS 2000) a potent enhancer mixed Th1/Th2 immune responses in mice immunized with HBsAg. Vaccine. 25 (2007) 4586–4594.
  19. V.K. Mohan. Recombinant human epidermal growth factor (REGEN-DTM 150): Effect on healing of diabetic foot ulcers. Diabetes Res. Clin. Pract. 78 (2007), 405-411.
  20. Dr.RajeshKesavan, Dr.Vijay Viswanathan, Ms.Sivagami, Ms.Kavitha, Dr.Mary Babu, Ms.Ramya. Dr. V. Krishna Mohan. Efficacy of Recombinant Human Epidermal Growth Factor (Regen D 150) in Healing Diabetic Foot Ulcers. Diabetes Res ClinPract. 2007 Dec;78(3):405-11. Epub 2007 Jul 25.
  21. Sabitha P., Prabha Adhikari M.R., Chowdary Abhijit, Prabhu Malathi, Soofimohammad, Shetty Meenakshi, Kamath Asha, Lokaranjan S.S., Bangera S.S. Comparison of the immunogenicity and safety of two different brands of salmonella typhi VI capsular polysaccharide vaccine. Indian J Med Sci 2004;58:141-9.